VYNE Therapeutics Inc. (VYNE) Stock Overview
Explore VYNE Therapeutics Inc.’s financial performance, market position, analyst ratings, and future outlook.
VYNE Therapeutics Inc. (VYNE)
Key Financials
Key Financials
Market Cap
19.1M
P/E Ratio
-0.04
EPS (TTM)
$-0.66
ROE
-2.00%
VYNE Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of VYNE Therapeutics Inc. (NASDAQ: VYNE) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, VYNE Therapeutics Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of VYNE on the NASDAQ shows an RSI of 88.92, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $1.19 for the NASDAQ listing.
Key metrics behind VYNE Therapeutics Inc.'s NASDAQ-traded stock include a P/E ratio of -0.04 and a market capitalization of 19.1M. Combined with our AI analysis, these give both institutional and retail investors a clear view of VYNE on the NASDAQ.